학술논문
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
Document Type
Article
Author
Source
In The Lancet Diabetes & Endocrinology December 2020 8(12):949-959
Subject
Language
ISSN
2213-8587